There is currently no structured training pathway for early career researchers, including allied healthcare professionals, in rare disease research. This gap is particularly evident in clinical trials methodology, trial delivery, and stakeholder engagement. The absence of rare disease-specific doctoral training programmes, limited post-doctoral funding, and a lack of cross-disciplinary training opportunities have contributed to career instability and challenges in retaining skilled researchers. Addressing these barriers is essential for building a sustainable rare disease research workforce and driving long-term improvements in patient care.
Our approach will focus on establishing a comprehensive training and capacity-building framework to support early career researchers in rare diseases. This includes the development of a translational science/clinical PhD training scheme to build expertise in rare disease research, alongside a dedicated professional and post-doctoral training fellowship scheme to provide structured career progression. Additionally, we will launch a cross-disciplinary training platform that integrates key areas such as genomics and rare disease clinical trials, ensuring researchers develop the complementary skill sets needed for translational research.
By embedding training and capacity building at the heart of the ARDT project, we will create a robust pipeline of skilled researchers. This effort will enhance career stability, foster interdisciplinary collaboration, and improve retention within the field. Ultimately, our work will strengthen the UK’s capability to conduct high-quality rare disease research, supporting the development and delivery of innovative treatments for people living with rare conditions.
We are always looking for talented researchers, clinicians, and industry partners to join our efforts in accelerating rare disease trials. Whether you’re interested in research collaboration, clinical trial design, or patient engagement, we’d love to hear from you.
LifeArc is a self-funded medical research charity. We take science ideas out of the lab and help turn them into medical breakthroughs that can be life-changing for patients. We have been doing this for more than 25 years and our work has resulted in five licensed medicines, including cancer drug pembrolizumab (Keytruda®), lecanemab for Alzheimer’s (Leqembi), and a diagnostic for antibiotic resistance.
Our teams are experts in drug and diagnostics discovery, technology transfer, and intellectual property. Our work is in translational science – bridging the gap between academic research and clinical development, providing funding, research and expert knowledge, all with a clear and unwavering commitment to having a positive impact on patient lives.
Find out more about our work on www.lifearc.org or follow us on LinkedIn or X.
The opinions and interpretations presented on this website are those of the authors and not LifeArc’s.
Newcastle University
Newcastle upon Tyne
Tyne and Wear
NE1 7RU
United Kingdom
The Centre is funded by LifeArc. LifeArc is a company limited by guarantee (registered in England and Wales under no. 2698321) and a charity (registered in England and Wales under no. 1015243 and in Scotland under no. SC037861).